Home › Oropharyngeal Cancer › NCT04151082
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
Stop LCNP: High Dose Steroid Therapy for Late Radiation-Associated Lower Cranial Neuropathy: A Phase I/II Dose Finding Trial and Data Registry
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * INCLUSION CRITERIA FOR CLINICAL TRIAL: Disease free adult survivors of oropharyngeal cancer * INCLUSION CRITERIA FOR CLINICAL TRIAL: Treated with radiotherapy \>= 2 years post treatment (disease status per surveillance imaging and clinical surveillance) * INCLUSION CRITERIA FOR CLINICAL TRIAL: Late radiation-associated lower cranial neuropathy of XII with or without X nerve (LCNP cases will be considered therapy-related when imaging, physical examination, and/or biopsy fail to demonstrate structural or malignant source) * INCLUSION CRITERIA FOR CLINICAL TRIAL: Willing and able to return for assessment post-steroid therapy * INCLUSION CRITERIA FOR CLINICAL TRIAL: Able to complete symptom survey (MD Anderson Symptom Inventory - Head and Neck \[MDASI-HN\]) in validated languages: English, simplified Chinese, Filipino, Greek, Japanese, Korean, Russian, Spanish, Taiwanese * INCLUSION CRITERIA FOR REGISTRY: Disease-free adult survivors of head and neck cancer * INCLUSION CRITERIA FOR REGISTRY: \>= 2 years post treatment (disease status per surveillance imaging and clinical surveillance) * INCLUSION CRITERIA FOR REGISTRY: Late lower cranial neuropathy of XII with or without X nerve (LCNP cases will be considered therapy-related when imaging, physical examination, and/or biopsy fail to demonstrate structural or malignant source) * INCLUSION CRITERIA FOR REGISTRY: Able to complete symptom survey (MDASI-HN) in validated languages: English, simplified Chinese, Filipino, Greek, Japanese, Korean, Russian, Spanish, Taiwanese Exclusion Criteria: * EXCLUSION CRITERIA FOR CLINICAL TRIAL: Uncontrolled diabetes * EXCLUSION CRITERIA FOR CLINICAL TRIAL: Uncontrolled hypertension (systolic \> 160; diastolic \> 90) * EXCLUSION CRITERIA FOR CLINICAL TRIAL: Known gastrointestinal ulcer * EXCLUSION CRITERIA FOR CLINICAL TRIAL: History of psychosis * EXCLUSION CRITERIA FOR CLINICAL TRIAL: Pregnant women * EXCLUSION CRITERIA FOR CLINICAL TRIAL: Untreated or treatment refractory obstructive pharyngoesophageal stricture * EXCLUSION CRITERIA FOR CLINICAL TRIAL: Known history or diagnosis of bipolar disorder * EXCLUSION CRITERIA FOR CLINICAL TRIAL: History of surgery near hypoglossal nerve path * EXCLUSION CRITERIA FOR REGISTRY: Uncontrolled diabetes * EXCLUSION CRITERIA FOR REGISTRY: Uncontrolled hypertension (systolic \> 160; diastolic \> 90) * EXCLUSION CRITERIA FOR REGISTRY: Known gastrointestinal ulcer * EXCLUSION CRITERIA FOR REGISTRY: History of psychosis * EXCLUSION CRITERIA FOR REGISTRY: Pregnant women * EXCLUSION CRITERIA FOR REGISTRY: Untreated or treatment refractory obstructive pharyngoesophageal stricture * EXCLUSION CRITERIA FOR REGISTRY: Known history or diagnosis of bipolar disorder
About the study
This phase I/II trial studies the side effect and best dose of steroid therapy (prednisone or methylprednisolone) in improving symptoms of late radiation-associated lower cranial neuropathy in oropharyngeal cancer survivors. Steroid therapy with prednisone or methylprednisolone may help to improve symptoms associated with late radiation-associated lower cranial neuropathy.
What is being tested
- Methylprednisolone (drug)
- Prednisone (drug)
- Quality-of-Life Assessment (other)
- Questionnaire Administration (other)
Sponsor: M.D. Anderson Cancer Center · Participants: 35 · Started: Oct 16, 2019
Contact the study team
- Katherine A Hutcheson, BA,MS,PHD · Phone: 713-792-6513
Official record on ClinicalTrials.gov — NCT04151082
Locations in the U.S.
| Texas | M D Anderson Cancer Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.